Weight LossTrendingHigh evidence

Semaglutide

GLP-1 receptor agonist widely used for weight management and glycemic control. The most clinically studied peptide in this class with multi-year outcome data.

Half-life

~7 days

Administration

Once-weekly subcutaneous injection

Primary uses

Weight management · Type 2 diabetes · Cardiometabolic risk

Mechanism

Mimics glucagon-like peptide-1, slowing gastric emptying, reducing appetite via central pathways, and improving insulin secretion in a glucose-dependent manner.

Weight management
Type 2 diabetes
Cardiometabolic risk

Dosing ranges

Educational ranges only — not medical advice. Confirm protocols with a qualified clinician.

Use case	Typical range	Frequency	Notes
Weight management (typical titration)	0.25 → 2.4 mg	Weekly	Escalate every 4 weeks as tolerated under clinician care
Glycemic control	0.5 → 1.0 mg	Weekly	Dose individualized to A1C response and tolerability

Clinical evidence

High evidence

N Engl J Med · 2021

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Mean body-weight reduction of ~14.9% at 68 weeks vs placebo.

View source

N Engl J Med · 2023

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

Reduced major adverse cardiovascular events in high-risk adults.

View source

Cautions

GI side effects are common during titration
Contraindicated with personal/family history of MTC or MEN2
Not a substitute for medical supervision

Provider comparison

Affiliate-style comparison cards for clinics, telehealth, and research suppliers. Verify licensing and product quality before purchasing.

Fountain Health

telehealth

4.7

From $249/mo

Licensed clinician consult + ongoing titration support

Compare offer

PeakRx Clinic

clinic

4.5

From $189/mo

In-person labs available in select metros

Compare offer

Research Supply Co.

research

4.1

Vial pricing

Research-only sourcing — not for human consumption labeling

View listing

Weight LossTrending